Discover innovative startups and track their funding journey
596 ventures found
596 ventures found
Leipzig, Germany
Medicruiter operates an integrated end-to-end platform for the international recruitment and long-term integration of nursing professionals. The solution combines structured process management, data-driven candidate selection, and standardized integration modules across the entire value chain—from international sourcing and language training to recognition processes and sustainable employment in Germany.
Cupertino, United States
Agentic automation for product and regulatory activities - from concept to quality to intelligence to labeling to submissions to post market surveillance.
Antwerpen, Belgium
Heran Partners helps organizations drive innovation and growth in the Healthcare and Life Sciences sectors by providing strategic insights and solutions.
Pillsbury is one of the world’s foremost law firms, operating at the intersection of technology innovation, capital and government. From microchips to blue chips, Pillsbury represents clients ranging from entrepreneurs working out of a garage to the largest public and private companies. The firm is known for market-leading transactional, disputes and regulatory practices, with teams of lawyers and business professionals collaborating across disciplines and delivering exemplary client service. Advising clients across the Americas, Europe, Asia, Africa and the Middle East, Pillsbury is consistently recognized for excellence by Chambers & Partners, The Legal 500, Financial Times and other publications. Attorney Advertising. Results depend on a number of factors unique to each matter. Prior results do not guarantee a similar outcome.
Lake Bluff, United States
Abbott is a global healthcare leader that provides innovative medical devices and health care solutions for cardiovascular health, diabetes management, diagnostic testing, nutrition, chronic pain, and more. With a diverse portfolio of life-changing tec...
Cambridge, United States
Xlife Sciences AG is a Swiss company focused on the value development of promising technologies in the life science sector. We invest in early stage medtech and lifesciences projects that help solve global health issues. Our goal is to bridge the gap b...
Aachen, Germany
PL BioScience is a biotech company and experts in cell culture supplements derived from human platelets. They offer a broad portfolio of human platelet lysate animal-free cell culture supplements that support cell expansion and maintenance from researc...
Germany
Surfacto BioTec is developing innovative life science tools based on bacterial surface proteins.
Switzerland
No description available
Insilico Medicine is a biotechnology company focused on leveraging generative artificial intelligence (AI) and automation for drug discovery and development. The company aims to accelerate and improve the process of discovering and developing novel therapeutics, with a focus on longevity and sustainability.
Germany
LoopLab is an emerging biotech company developing a first-in-class Fc-Engager platform to induce antigen-specific immune tolerance. Our lead program, LL-HDM, targets house dust mite (HDM) allergy – a major cause of perennial allergic rhinitis and asthma – with a short-course biologic designed to “re-educate” the immune system rather than just suppress symptoms. By fusing disease-specific antigens to an engineered inhibitory Fc domain, our Fc-Engagers selectively silence pathogenic B cells and promote regulatory pathways, aiming for durable remission with minimal systemic immunosuppression. The same modular platform can be rapidly adapted to autoimmune diseases (e.g. celiac disease, bullous pemphigoid) and to prevent anti-drug antibodies against biologics. We are currently in late preclinical development for LL-HDM, supported by €9.6M in seed funding and €1.5M in grants, and preparing a Series A financing of €30–50M in 2026 to reach IND (2027) and First-in-Human (2028). LoopLab is led by a seasoned team with deep experience in immunotherapy, CMC, and clinical development from MSD, Themis, Valneva, Evotec, and others, complemented by an advisory board with strong pharma partnering and clinical trial expertise. Our strategy is to achieve early clinical proof-of-concept in HDM allergy, then monetize via out-licensing and platform partnerships while expanding into high-value autoimmune indications.
Saltsjö Boo, Sweden
Company Overview Utilizer is a MedTech start-up from KTH Royal Institute of Technology, focused on Point-of-Care (POC) diagnostics for bacterial infections. Our mission: - Responsible use of Antibiotics - Save healthcare costs - Improve patient outcomes Solution – First product for market for Urinary Tract Infections, Utilizer®-ID - Miniaturized culture-based diagnostic tool for UTIs at POC - Gold-standard accuracy, results in hours, analyzed via smartphone in 10 seconds - No lab equipment investment - Covers >95% of UTI pathogens - Patent granted in US, pending EU Clinical Validation - Trials at Karolinska: 96% sensitivity, 87% specificity - Usability study at 4 POC sites showing ease of use and fit in current POC workflow with 100% users recommending it for others - IVDR certification in progress Next product in pipeline, Utilizer AST bacterial resistance testing Exit strategy Diagnostic or microbiology company (Roche Diagnostics, Thermo Scientific, Abbott, Biomérieux, Siemens) within 5 years
Boston, United States
ReMinded, Inc. is a MedTech startup on a mission to become the leading solution in salivary diagnostics. Currently, the team is commercializing the first clinical-grade, rapid saliva test that tracks cortisol(a key stress hormone)on demand, unlocking a vital biomarker for psychiatry and behavioral health. The system syncs seamlessly to a desktop platform, enabling clinicians and patients to monitor stress in real-time, reducing reliance on solely subjective assessments for e.g addiction treatment decisions and PTSD.
San Diego, United States of America
LipoNexus is commercializing the first highly accurate, non-invasive blood test for early detection of Metabolic Associated Steatotic Liver Disease (MASLD).
United States of America
AOA Dx is closing the gap with AKRIVIS GD, a first-of-its-kind multi-omic blood test for ovarian cancer detection in symptomatic women.
Switzerland
sefit develops a clinically guided VR-based digital therapeutic designed to support individuals with autism, ADHD and migraine in managing sensory overload.
Basel, Switzerland
BRNLIT.AI offers a personalised, non-pharmacological digital therapeutic using EEG-based light-stimulation to improve focus and attention regulation.
Canada
mTatt is a medtech startup developing functional microtattoos for real-time, at-home health monitoring using dissolving microneedles.
Austria
Long-term organ perfusion as a preclinical platform for drug testing.
Canada
Nimble Science is transforming gastrointestinal health with the SIMBA Capsule - a swallowable, single-use device that safely collects endoscopic-quality fluid samples from the small intestine.
Germany
SURFACtoBioTech is building the first full‑stack droplet experimentation platform that unites proprietary surfactant chemistry, automated hardware and AI‑enabled analytics into one ecosystem. Our technology converts microliter‑scale samples into 100,000 uniform picoliter droplets from just 10 µL, generating orders of magnitude more high‑quality data at dramatically lower cost and turnaround time. Installed as modular instruments with integrated consumables and software, our platform enables academic, diagnostic and pharma customers to perform high‑throughput assays, structural biology experiments and screening workflows that are currently too slow, expensive or manpower‑intensive. With two patent families covering surfactant chemistry and system integration, >90% blended gross margins and three recurring revenue streams (platform, consumables, software), SURFACtoBioTech is positioned to become the category‑defining infrastructure provider in droplet microfluidics.
SeeQ develops rapid metagenomics-based precision diagnostics for any clinically relevant pathogen from less than 1 mL blood in 6-8 hours. This approach enables faster, more targeted antimicrobial treatment, for better patient outcomes with reduced adverse events and improved quality of life. In turn, health care usage is reduced through shorter hospital stays, lowered readmittance rates and improved antimicrobial stewardship. Our first product, SepSeeQ, has been evaluated into two prospective clinical trials in an acute care setting and chronic infections related to vascular grafts, with additional two studies ongoing in neonatal sepsis and hematological cancers.
We provide a validated pulsatile endovascular aortic training simulator that has already been used in pilot courses both in the angio suite and in dry-lab settings. In a second step, we are developing complementary high-fidelity 3D-printed open vascular models so that the same training center can cover both endovascular and open vascular procedures in a structured 1–2 day course format.
Synagen builds oncology-specific AI agents that automate tumor-board decisions, guideline-based treatment suggestions, and clinical-trial matching, giving every cancer patient access to expert-level care at every visit. We integrate deeply into hospital workflows, reduce documentation and preparation time, and continuously generate structured precision-oncology data that improves outcomes and enables large-scale research over time.
Page 1 of 25